The estimated Net Worth of Robert L Myers is at least $333 Tysiąc dollars as of 25 September 2023. Mr Myers owns over 1,667 units of Predictive Oncology stock worth over $4,969 and over the last 8 years he sold POAI stock worth over $0. In addition, he makes $327,838 as CFO & Sec. at Predictive Oncology.
Mr has made over 5 trades of the Predictive Oncology stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 1,667 units of POAI stock worth $1,584 on 25 September 2023.
The largest trade he's ever made was exercising 33,334 units of Predictive Oncology stock on 23 September 2021 worth over $37,667. On average, Mr trades about 9,325 units every 73 days since 2016. As of 25 September 2023 he still owns at least 5,230 units of Predictive Oncology stock.
You can see the complete history of Mr Myers stock trades at the bottom of the page.
Robert L. Myers is the CFO & Sec. at Predictive Oncology.
As the CFO & Sec. of Predictive Oncology, the total compensation of Mr Myers at Predictive Oncology is $327,838. There are 1 executives at Predictive Oncology getting paid more, with Dr. Carl I. Schwartz having the highest compensation of $433,000.
Mr Myers is 66, he's been the CFO & Sec. of Predictive Oncology since . There are 4 older and 5 younger executives at Predictive Oncology. The oldest executive at Predictive Oncology Inc. is Dr. Carl I. Schwartz, 79, who is the CEO & Director.
Robert's mailing address filed with the SEC is 8070 UPPER 146TH STREET WEST, , APPLE VALLEY, MN, 55124.
Over the last 5 years, insiders at Predictive Oncology have traded over $30,944 worth of Predictive Oncology stock and bought 417,770 units worth $148,589 . The most active insiders traders include Carl I. Schwartz, J Melville Engle oraz Charles Lee Sr Nuzum. On average, Predictive Oncology executives and independent directors trade stock every 71 days with the average trade being worth of $29,495. The most recent stock trade was executed by Robert L Myers on 25 September 2023, trading 1,667 units of POAI stock currently worth $1,584.
Predictive Oncology Inc., a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence (AI) primarily in the United States. The company operates in four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment offers clinical testing services comprising tumor drug response testing and genomic profiling tests; and contract research services through patient-centric drug discovery using active learning technology for discovery, clinical and translational research, clinical trials, and diagnostic development and validation. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using High-Throughput Self-Interaction Chromatography, a self-contained, automated system that conducts high-throughput, self-interaction chromatography screens using additives and excipients that are included in protein formulations for soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates staff exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. It also offers research and development services; and media that help cancer cells grow outside the patient's body and retain their DNA/RNA and proteomic signatures. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is based in Eagan, Minnesota.
Predictive Oncology executives and other stock owners filed with the SEC include: